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Gastrointestinal malignancies other than colorectal cancer (CRC)
are common. In Israel in 1995, gastric cancer was diagnosed in
572 Jewish individuals, pancreatic cancer in 368, 140 were diag-
nosed with primary liver or biliary tract cancer, and 110 had
oesophageal cancer (Israel Cancer Registry, 1998). Furthermore,
the mortality rate from gastric and pancreatic cancer is high: in
Israel the age stratified rate (ASR) for gastric cancer mortality is
10.9/100 000 in Jewish men and 5.6/100 000 in Jewish women,
compared with an ASR for morbidity of 14.2/100 000 and 7.7/
100 000, respectively (Israel Cancer Registry, 1998). This high
mortality rate stems in part from the paucity of early symptoms
and hence the advanced stage at which these neoplasms are
usually diagnosed. Thus, identifying individuals at high risk for
developing these malignancies has obvious clinical implications.
Familial clustering of cancer, a well known risk factor predis-
posing to gastric, pancreatic, and other GI cancer is noted in
3–10% of all incident cases of these malignancies (Zanghieri et al,
1990; Lynch et al, 1992; Fernandez et al, 1994). The relative risk
for developing gastric cancer in first-degree relatives of gastric
cancer patients ranges from 1.7 to 3.5, with an increase in relative
risk associated with having more than one affected family member
(Zanghieri et al, 1990; Palli et al, 1994; Lissowska et al, 1999).
Similarly, familial clustering of pancreatic cancer is associated
with an increased risk for developing these neoplasms in all first
degree relatives (Ghadirian et al, 1991; Lynch et al, 1992). These
observations suggest an inherited predisposition to these cancer
types in a subset of patients, but the genes that underlie this genetic
susceptibility remain largely unknown. Clustering of ovarian and
gastric cancer (Easton et al, 1996) and breast/ovarian and exocrine
pancreatic cancer (Tulinius et al, 1992) have been reported,
suggesting a role for BRCA2 gene mutations in pancreatic cancer
predisposition (Phelan et al, 1996). Furthermore, a large study
encompassing more than 3000 BRCA2 mutation carriers and their
first-degree relatives, estimated the relative risk (RR) for devel-
oping cancers other than breast/ovarian: for pancreatic cancer the
RR was 3.51, for gallbladder and bile duct cancer – 4.97 and for
stomach cancer – 2.59 (BCLC, 1999). 
Among Jewish people, a single predominant mutation within
the BRCA2 gene (6174delT) occurs. This mutation can be detected
in individuals at risk for developing breast and ovarian cancer
(Abeliovich et al, 1997), in about 1–1.5% of the general Ashkenazi
(East European) Jews (Ouddoux et al, 1996; Roa et al, 1996), and
rarely among non-Ashkenazi Jews (Struewing et al, 1999).
Analysis of 245 unselected patients with pancreatic cancer for this
mutation, revealed two mutation carriers (0.8%) and an additional
BRCA2 germline mutation carrier in a nearby codon (Goggins et
al, 1996). However, not all patients in this latter study were Jewish
individuals. Direct mutational analysis of 39 unselected Jewish
Ashkenazi patients with pancreatic cancer, revealed 4 6174delT
BRCA2 (10%) mutation carriers (Ozcelik et al, 1997). 
To test the notion that BRCA2 mutations predispose to gastroin-
testinal malignancies other than colorectal cancer, we determined
the rate of the BRCA2 6174delT predominant germline mutation in
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70 unselected Jewish Ashkenazi patients with these types of
malignancies who were consecutively treated in a single medical
centre in Israel. 
MATERIALS AND METHODS 
Patients’ characteristics and tumour material 
All patients with a clinical and histopathological diagnosis of
gastrointestinal malignancy (excluding colorectal cancer) who were
treated at the Institute of Oncology, Rabin Medical Center from
January 1, 1999 to March 31, 2000, were eligible for participation.
The study was approved by the institutional review board, and all
patients signed an informed consent. All consenting patients filled a
detailed questionnaire that includes demographic data, past medical
history, age at diagnosis, family history of cancer, especially
gastrointestinal, breast and/or ovarian. Based on the criteria applied
for other familial cancers, patients having at least one first-degree
relative with GI or BRCA2 related cancer (breast and ovarian), or
more than two second-degree relatives with cancer one of which is
of GI, breast or ovarian origin, were classified as familial cases. 
DNA extraction 
Anticoagulated peripheral blood was withdrawn by venopuncture,
and DNA was extracted using standard techniques, using the
Gentra kit (Gentra Inc., Minneapolis, MN). 
Mutation analysis of the predominant Jewish mutation
in BRCA2 
Mutational analyses for the predominant mutation (6174delT) in
BRCA2, were carried out by restriction enzyme digest of amplified
PCR products using modified amplification primers, to generate
novel restriction sites, followed by restriction enzyme analysis to
distinguish the mutant from the wild-type allele, as previously
described (Rohlfs et al, 1997), and adopted by us (Bar Sade et al,
1998). 
Statistical analyses 
Comparison of the rates of the founder Jewish mutation in BRCA2
between the general Jewish Ashkenazi population (Hartage et al,
1999) and all GI cancer patients in our study group as well as the
distribution within specific tumour types were performed using
Fisher’s Exact test. Odds ratio (OR) and the 95% confidence inter-
vals (CI) were calculated from the tables 
Even though the numbers for the Jewish Ashkenazi population
are based on American Ashkenazi Jews (Hartage et al, 1999), we
assumed that it is legitimate to use these numbers for two main
reasons: first, the Ashkenazi Jewish population is well character-
ized as a distinct ethnic entity, regardless of the present place of
residence (i.e. Tel-Aviv or Washington). Second, comparisons of
Israeli and non-Israeli Ashkenazis with regard to being 185delAG
BRCA1 mutation carriers, did not show any differences between
Israelis and Americans (Streuwing et al, 1997). 
RESULTS 
Patients’ characteristics 
All 70 were of Ashkenazi origin. The most common malignancy
was gastric cancer (n = 35), followed by exocrine pancreatic
cancer (n = 23), oesophageal cancer (n = 7), bile duct cancer (n =
4) and one small bowel cancer. Median age at diagnosis was 67
years (range 38–90 years) with a mean age of 65.8±11.8 years;
6 patients (8.57%) were diagnosed between 38–49 years; 16
(22.8%) – between 50–59 years; 19 (27.2%) – between 60–69
years; 20 (28.6%) – between 70–79 years; 9 (12.8%) over the age
of 80 years. 13 (18.5%) and 12 (17.1%) patients had first-degree
relatives with gastrointestinal or other cancer, respectively, and 4
(5.7%) had at least one first-degree relative with breast cancer. 
Germline mutational analysis 
The presence of 6174delT BRCA2 germline mutation was tested in
all study participants and 6 carriers were found (6/70–8.6%). The
clinical and pertinent data of the 6 mutation carriers are presented
in Table 1. Notably, 3/23 of the patients with pancreatic cancer
(13%), 2/35 (5.7%) of the patients with gastric cancer and 1/4 of
the patients (25%) with bile duct cancer were mutation carriers.
Surprisingly, only 1/5 individuals with a family history of breast
and/or ovarian cancer was among the mutation carriers, and family
history of other cancer was ascertained in 4/6 mutation carriers
(Table 1). In addition, the age at diagnosis in mutation carriers was
not noticeably younger than other individuals with the same
cancer type. 
Statistical analyses 
There was a statistically significant difference in the carrier rate of
the 6174delT BRCA2 mutation between the general Jewish
Ashkenazi population and all cancer types in the present study
Table 1 Clinical and histopathological data of all BRCA2 mutation carriers
in the present study 
Pat no. Sex Tumour Age at diagnosis Family history of
cancer 
1 M Bile duct cancer 60 Father – CRC 
Son – CRC 
2 F Gastric 55 None 
3 F Gastric 54 Mother – BC 
Grandmother – BC 
4 M Pancreas 54 Mother – CRC 
5 M Pancreas 81 None 
6 M Pancreas 61 Mother – abdominal
cancer 
BC = Breast cancer; CRC = colorectal cancer. 
Table 2 Comparison between the mutation carrier rate of the predominant
Jewish mutation in BRCA2 in the study population (Israeli Ashkenazi GI
cancer patients) and the reference Jewish Ashkenazi population (from
Hartage et al, 1999) by specific tumour types 
Cancer type Mutation carriers P value OR CI 
Gastric 2/35 (5.7%) 0.06 5.2 1.2–22 
Pancreatic 3/23 0.002 12.8 3.7–44.2 
Bile duct 1/4 0.05 28.4 2.9–277.2 
Oesophageal 0/7 NS – – 
Small intestine 0/1 NS – – 
Total 6/70 (8.6%) 0.0002 8 3.3–19.2 
NS – denotes statistically not significant. 480 A Figer et al 
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combined (59/5089 vs. 6/70, P = 0.0002). Analysis of the rate of
this mutation within specific tumour types, showed that the rates in
pancreatic cancer and bile duct cancer were also statistically
significant higher than population controls (Table 2). 
DISCUSSION 
In the present study, the involvement of the BRCA2 gene in inher-
ited predisposition to gastrointestinal cancer other than colorectal
cancer was evaluated by direct mutational analysis. The rate of the
predominant Jewish mutation in BRCA2 in Ashkenazi patients
with gastric, exocrine pancreatic cancer and bile duct cancer was
significantly greater than the rate in the general Jewish Ashkenazi
population (Struewing et al, 1997; Hartage et al, 1999).
Furthermore, family history of cancer was elucidated in 4/6 muta-
tion carriers, as an additional evidence that the mutation found is
not merely an incidental finding, but rather reflects a true inherited
predisposition. 
The data presented herein are in agreement with other studies
showing a higher than expected rate of BRCA2 gene germline
mutations in pancreatic cancer in ethnically diverse populations,
and in Ashkenazi Jews, in particular. The original observation
regarding finding of 2/245 (0.8%) 6174delT mutation carriers and
4/39 (10%) among unselected patients (Goggins et al, 1996) or
Jewish individuals (Ozelick et al, 1997) with pancreatic cancer has
been mentioned. Analysis of 38 Jewish individuals with pancreatic
cancer, revealed 3 (7.9%) BRCA2 6174delT mutation carriers (Lal
et al, 2000). Furthermore, in Iceland, where a single predominant
mutation (999del5) in BRCA2 exists, first-degree relatives of
mutation carriers had a higher than expected rate of pancreatic
cancer (Thorlacius et al, 1997). The role of BRCA2 mutations in
conferring genetic susceptibility to gastric, oesophageal, hepatic
and biliary tract cancer is much less established. A high rate of
allelic loss at the BRCA2 locus has been reported, but few somatic
mutations have been detected in BRCA2 in hepatocellular cancer
(Katagiri et al, 1996). Similarly, 93% of oesopahgeal cancer from
patients with a family history of the disease (n = 23), displayed
allelic loss with a marker from the long arm of chromsome 13
(D13S894) (Hu et al, 1999). Moreover, in the most comprehensive
study of cancer types other than breast and ovarian, associated
with germline BRCA2 mutations, up to five-fold increased risk for
biliary tract and more than double the risk for stomach cancer is
reported (BCLC, 1999). However, to the best of our knowledge,
no direct mutational analyses studies were ever performed in
individuals with these latter cancer types. 
The results of the present study which support other lines of
indirect evidence as to the involvement of BRCA2 germline muta-
tions in the susceptibility to cancer of the upper gastrointestinal
tract, should be reflected in genetic counselling. The increased risk
for developing these malignancies should be incorporated into the
routine counselling process, and surveillance schemes aimed at
early detection of these cancer types should be devised and tested.
Furthermore, the subset of Ashkenazi Jewish patients with either
gastric, pancreatic cancer or bile duct cancer and a strong family
history of cancer should probably all be tested for being BRCA2
mutation carriers. 
In conclusion, in Jewish individuals, germline mutations in the
BRCA2 gene seem to contribute to the genetic susceptibility to
gastric, exocrine pancreatic and/or biliary tract cancer, and a
family history of these or related cancer types. The predictive
value, penetrance and the lifetime risk for developing these
neoplasms in Jewish BRCA2 mutation carriers remains to be deter-
mined in a larger, prospective study. 
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